LQDA
Liquidia Corp
NASDAQ · Healthcare · Biotechnology · US
$65.31
−2.15%Price chart
Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14
ValuationView details →
P/E (Fwd)
14.7x
EV/EBITDA
32.0x
Market Cap
$5.85B
MomentumView details →
1D Return
−2.15%
YTD Return
+92.17%
RSI (14)
37.3
ValuationView details →
P/E (Fwd)
14.7x
EV/EBITDA
32.0x
Market Cap
$5.85B
RSI (14)
37.3
MomentumView details →
1D Return
−2.15%
YTD Return
+92.17%
SummaryUpdated Jun 1, 2026
Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company founded in 2004 and headquartered in Morrisville, North Carolina. The company went public in July 2018 and focuses on developing and commercializing innovative treatments for rare diseases, particularly pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia utilizes its proprietary PRINT technology platform to create precisely engineered drug particles that can improve the delivery and efficacy of existing medications.
Similar companies
Latest newsMore news →
The FDA granted Fast Track designation to Liquidia's Yutrepia for the treatment of Raynaud's phenomenon associated with systemic sclerosis.5d agoOn August 20, 2026, Liquidia Corp's shares fell 5.8% to $71.05, continuing a decline from its 52-week high of $93.61.25d agoLiquidia's YUTREPIA commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially.33d ago